Directed Cardiomyocyte Differentiation via Two-Step Chemical Protocol
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating human embryonic stem cells into ventricular cardiomyocytes are inefficient, producing low yields and heterogeneous populations, requiring genetic manipulation, and are costly and cumbersome, limiting their use in therapeutic applications.
Innovation Solution
A fully chemically defined, two-step differentiation protocol using recombinant growth factors and small molecules efficiently differentiates embryonic stem cells, including human embryonic stem cells and induced pluripotent stem cells, into ventricular-like cardiomyocytes, achieving high purity and scalability without genetic manipulation or cell sorting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current cardiomyocyte differentiation methods are used, then cardiomyocytes can be generated, but the yield is low and the cell population is heterogeneous
Solution Approach 1:
The differentiation process is divided into distinct sequential stages: initial cardiomyocyte differentiation using BMP4 and FGF2, followed by ventricular specification using IWR-1 and purmorphamine. This segmentation allows each stage to optimize for its specific goal, achieving both high yield and high purity ventricular cardiomyocytes
Solution Approach 2:
The protocol applies preliminary ventricular specification cues (IWR-1 and purmorphamine) after initial cardiomyocyte formation. This preliminary action ensures that as cardiomyocytes differentiate, they are simultaneously directed toward the ventricular lineage, preventing heterogeneity before it occurs
2Manufacturing precision
If genetic manipulation with viral vectors is used to generate pure populations, then purity can be achieved, but the complexity and cost increase and therapeutic applicability decreases
Solution Approach 1:
The differentiation protocol uses chemically defined media with recombinant growth factors and small molecules that guide stem cells to self-differentiate into pure ventricular cardiomyocyte populations without requiring external genetic manipulation, sorting, or selection processes
Solution Approach 2:
The protocol uses transient exposure to small molecules (IWR-1, purmorphamine) and growth factors that are removed after differentiation, replacing permanent genetic manipulation with temporary chemical cues that achieve the same purifying effect
3Manufacturing precision
If multiple growth factors and inhibitors are used in differentiation protocols, then differentiation can be achieved, but the cost increases and scalability decreases
Solution Approach 1:
The protocol extracts and eliminates serum and other animal-based products from the differentiation media, replacing them with chemically defined components. This extraction of undefined materials reduces batch-to-batch variability and enables scalable manufacturing while maintaining high differentiation efficiency
Solution Approach 2:
The protocol uses defined concentrations of recombinant growth factors (BMP4, FGF2) and small molecules (IWR-1, purmorphamine) at specific time points, optimizing the parameters of chemical exposure to achieve consistent high-yield ventricular cardiomyocyte differentiation across multiple batches
Data Source
AI summary
Disclosed is a fully chemically defined, small molecule-mediated, directed differentiation system that promotes differentiation of stem cells, including embryonic stem cells, induced pluripotent stem cells, and adult stem cells, such as human forms of these stem cell types, to ventricular cardiomyocytes in a highly efficient, reproducible and scalable fashion. Also disclosed is a cost-effective and efficient protocol, or method, for generating cardiomyocytes and a cost-effective and efficient method of maturing cardiomyocytes. The disclosed differentiation system provides a platform to perform large-scale pharmacological screenings and to provide a valuable source of each of cardiac progenitor cells and cardiomyocytes for cell replacement therapies in cardiac repair.